News & Events

Corporate Presentation
News Releases
Acquisition of Stemline establishes Menarini’s presence in the U.S. biopharmaceutical oncology market  Menarini will support further development of Stemline’s ELZONRIS ® and enable global expansion by leveraging its commercial infrastructure in Europe and other ex- U.S.

Additional Formats

Net revenue for ELZONRIS® was $11.8 million for the fourth quarter Conference call and live webcast scheduled for Monday, March 16 th , at 8:00 AM ET NEW YORK , March 13, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the

Additional Formats

NEW YORK , March 11, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that the company will host a conference call and webcast on Monday,

Additional Formats

NEW YORK , Feb. 26, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that management will present at the Cowen 40 th Annual Health Care

Additional Formats

NEW YORK , Jan. 13, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced preliminary net revenues for 2019, as well as outlined key BPDCN

Additional Formats

Upcoming Events
More events are coming soon.